EU offers incentives to firms to produce medicines for childrenBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7554.1352-c (Published 08 June 2006) Cite this as: BMJ 2006;332:1352
- Rory Watson
Pharmaceutical companies are being encouraged to develop medicines specifically for children, under European Union legislation approved this week.
The new rules, which are expected to come into force early next year, will reward firms that produce new paediatric drugs by giving them a six month extension to their patents. Manufacturers of orphan medicines for children will enjoy an extra two years of market exclusivity on top of the 10 years already in operation for adult drugs.
Françoise Grossetête, the French Conservative MEP who steered the legislation through the European Parliament, said that it would …
Log in using your username and password
Log in through your institution
Sign up for a free trial